Trevi Therapeutics (TRVI) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $12.11, +0.41% vs the prior close of $12.06.
- Volume 1.71M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TRVI rises 0.4% to $12.11. Closed at $12.11, +0.41% vs the prior close of $12.06. Day range $11.98–$12.39, opened at $12.06.
TRVI daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — TRVI rises 0.4% to $12.11
- Closed at $12.11, +0.41% vs the prior close of $12.06. Day range $11.98–$12.39, opened at $12.06.
- Volume was 1.71M shares, 0.8x its 50-day average of 2.02M.
- Price is -23.8% vs its 50-day average ($15.88) and -15.1% vs its 200-day average ($14.27).
- 52-week range $9.82–$20.22; today's close sits at 22% of that range, 40.1% below the 52-week high.
Oct 14, 2026 — TRVI dips 1.9% to $12.06, a 6-month low, 3 down days in a row
- Closed at $12.06, -1.87% vs the prior close of $12.29. Day range $12.00–$12.55, opened at $12.03.
- Volume was 3.04M shares, 1.5x its 50-day average of 2.01M.
- Price is -24.7% vs its 50-day average ($16.02) and -15.5% vs its 200-day average ($14.28).
- 52-week range $9.28–$20.22; today's close sits at 25% of that range, 40.4% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — TRVI slides 4.9% to $12.29, a 6-month low
- Closed at $12.29, -4.95% vs the prior close of $12.93. Day range $12.29–$13.19, opened at $12.86.
- Volume was 1.58M shares, 0.8x its 50-day average of 2.00M.
- Price is -23.9% vs its 50-day average ($16.15) and -13.9% vs its 200-day average ($14.28).
- 52-week range $9.28–$20.22; today's close sits at 28% of that range, 39.2% below the 52-week high.
Oct 12, 2026 — TRVI dips 2.0% to $12.93 on 2.5x normal volume
- Closed at $12.93, -1.97% vs the prior close of $13.19. Day range $12.81–$13.46, opened at $13.14.
- Volume was 4.77M shares, 2.5x its 50-day average of 1.93M — unusually heavy trading.
- Price is -20.5% vs its 50-day average ($16.26) and -9.5% vs its 200-day average ($14.28).
- 52-week range $9.28–$20.22; today's close sits at 33% of that range, 36.1% below the 52-week high.
Oct 9, 2026 — TRVI rises 2.8% to $13.19 on 2.7x normal volume
- Closed at $13.19, +2.85% vs the prior close of $12.82. Day range $12.52–$13.30, opened at $13.09.
- Volume was 5.03M shares, 2.7x its 50-day average of 1.86M — unusually heavy trading.
- Price is -19.4% vs its 50-day average ($16.37) and -7.6% vs its 200-day average ($14.28).
- 52-week range $9.28–$20.22; today's close sits at 36% of that range, 34.8% below the 52-week high.
Oct 8, 2026 — TRVI dips 2.4% to $12.82, a 6-month low on 3.6x normal volume
- Closed at $12.82, -2.40% vs the prior close of $13.14. Day range $12.32–$13.28, opened at $12.96.
- Volume was 6.35M shares, 3.6x its 50-day average of 1.76M — unusually heavy trading.
- Price is -22.1% vs its 50-day average ($16.47) and -10.2% vs its 200-day average ($14.28).
- 52-week range $9.28–$20.22; today's close sits at 32% of that range, 36.6% below the 52-week high.
- That makes 7 straight losses.
Oct 7, 2026 — TRVI dips 0.3% to $13.14, a 3-month low on 3.2x normal volume
- Closed at $13.14, -0.30% vs the prior close of $13.18. Day range $12.84–$13.53, opened at $12.94.
- Volume was 5.37M shares, 3.2x its 50-day average of 1.69M — unusually heavy trading.
- Price is -20.7% vs its 50-day average ($16.58) and -8.0% vs its 200-day average ($14.28).
- 52-week range $9.28–$20.22; today's close sits at 35% of that range, 35.0% below the 52-week high.
- That makes 6 straight losses.
Oct 6, 2026 — TRVI slides 3.9% to $13.18, a 3-month low on 3.1x normal volume
- Closed at $13.18, -3.94% vs the prior close of $13.72. Day range $12.99–$13.97, opened at $13.83.
- Volume was 5.00M shares, 3.1x its 50-day average of 1.63M — unusually heavy trading.
- Price is -21.0% vs its 50-day average ($16.68) and -7.7% vs its 200-day average ($14.28).
- 52-week range $9.28–$20.22; today's close sits at 36% of that range, 34.8% below the 52-week high.
- That makes 5 straight losses.
Oct 5, 2026 — TRVI dips 1.4% to $13.72, a 3-month low, 4 down days in a row
- Closed at $13.72, -1.37% vs the prior close of $13.91. Day range $13.51–$14.11, opened at $13.97.
- Volume was 1.72M shares, 1.1x its 50-day average of 1.62M.
- Price is -18.2% vs its 50-day average ($16.78) and -3.9% vs its 200-day average ($14.27).
- 52-week range $9.28–$20.22; today's close sits at 41% of that range, 32.1% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — TRVI dips 1.9% to $13.91, a 3-month low, 3 down days in a row
- Closed at $13.91, -1.90% vs the prior close of $14.18. Day range $13.72–$14.55, opened at $14.38.
- Volume was 2.08M shares, 1.3x its 50-day average of 1.63M.
- Price is -17.5% vs its 50-day average ($16.86) and -2.5% vs its 200-day average ($14.26).
- 52-week range $9.28–$20.22; today's close sits at 42% of that range, 31.2% below the 52-week high.
- That makes 3 straight losses.
TRVI latest news & SEC filings
Every SEC filing by or about TRVI in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Heffernan Michael Thomas converted options/RSUs into 18,421 shares at $3.04 (≈$56.00K) on Sep 15, 2026; now holds 24,772
- Heffernan Michael Thomas sold 18,321 shares at $15.09 (≈$276.46K) on Sep 15, 2026; now holds 6,451
- Heffernan Michael Thomas sold 100 shares at $15.88 (≈$1.59K) on Sep 15, 2026; now holds 6,351
- Heffernan Michael Thomas converted options/RSUs into 21,052 shares at $3.33 (≈$70.10K) on Sep 15, 2026; now holds 27,403
- Heffernan Michael Thomas sold 20,952 shares at $15.09 (≈$316.17K) on Sep 15, 2026; now holds 6,451
- Heffernan Michael Thomas sold 100 shares at $15.88 (≈$1.59K) on Sep 15, 2026; now holds 6,351
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 6, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$17.80M (prior year -$12.30M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.11 (prior year -$0.09) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade TRVI
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Apr 17, 2026, Mar 17, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.84% (largest 5.1%).
- Liquidity: about 2.78M shares (≈$33.67M) trade per day on average.
- 52-week position: $12.11 vs a range of $9.82–$20.22 (22% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Michael Thomas Heffernan sold 18,321 shares on Sep 15, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 4, 2026.
- Share count: 142.48M shares outstanding (Jul 31, 2026), +17.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TRVI market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 12.06 | 12.39 | 11.98 | 12.11 | 1.71M |
| Oct 14, 2026 | 12.03 | 12.55 | 12.00 | 12.06 | 3.04M |
| Oct 13, 2026 | 12.86 | 13.19 | 12.29 | 12.29 | 1.58M |
| Oct 12, 2026 | 13.14 | 13.46 | 12.81 | 12.93 | 4.77M |
| Oct 9, 2026 | 13.09 | 13.30 | 12.52 | 13.19 | 5.03M |
| Oct 8, 2026 | 12.96 | 13.28 | 12.32 | 12.82 | 6.35M |
| Oct 7, 2026 | 12.94 | 13.53 | 12.84 | 13.14 | 5.37M |
| Oct 6, 2026 | 13.83 | 13.97 | 12.99 | 13.18 | 5.00M |
| Oct 5, 2026 | 13.97 | 14.11 | 13.51 | 13.72 | 1.72M |
| Oct 2, 2026 | 14.38 | 14.55 | 13.72 | 13.91 | 2.08M |
| Oct 1, 2026 | 14.30 | 14.66 | 14.08 | 14.18 | 3.15M |
| Sep 30, 2026 | 14.48 | 14.77 | 14.27 | 14.32 | 2.73M |
| Sep 29, 2026 | 14.40 | 14.75 | 14.15 | 14.42 | 2.05M |
| Sep 28, 2026 | 14.30 | 14.57 | 14.16 | 14.40 | 1.61M |
| Sep 25, 2026 | 14.68 | 14.75 | 14.33 | 14.41 | 1.36M |
| Sep 24, 2026 | 14.27 | 14.72 | 14.00 | 14.68 | 1.70M |
| Sep 23, 2026 | 15.08 | 15.20 | 14.41 | 14.46 | 1.35M |
| Sep 22, 2026 | 15.15 | 15.27 | 14.92 | 15.24 | 1.23M |
| Sep 21, 2026 | 14.96 | 15.11 | 14.59 | 14.89 | 1.65M |
| Sep 18, 2026 | 15.17 | 15.38 | 14.81 | 14.95 | 2.14M |
About Trevi Therapeutics
Trevi Therapeutics (TRVI) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW HAVEN, CT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1563880.
TRVI board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Dominick Colangelo | Director | Jun 4, 2026 |
| Jennifer L Good | President & CEO | Feb 20, 2026 |
| Michael Thomas Heffernan | Director | Sep 17, 2026 |
| Edward T Mathers | Director | Jun 4, 2026 |
| David P Meeker | Director | Jun 4, 2026 |
| Anne Vanlent | Director | Jun 4, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James V Cassella | Chief Development Officer | Feb 20, 2026 |
| Jennifer L Good | President & CEO | Feb 20, 2026 |
| Christopher Galletta | See Remarks | Feb 20, 2026 |
| David C Hastings | Chief Financial Officer | Jan 12, 2026 |
| Thomas Sciascia | Chief Scientific Officer | Feb 20, 2026 |
| Farrell Simon | Chief Commercial Officer | Feb 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Michael Thomas Heffernan | Sale | 18,321 | $15.09 |
| Sep 15, 2026 | Michael Thomas Heffernan | Sale | 100 | $15.88 |
| Sep 15, 2026 | Michael Thomas Heffernan | Sale | 20,952 | $15.09 |
| Sep 15, 2026 | Michael Thomas Heffernan | Sale | 100 | $15.88 |
TRVI financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-42.76M | -0.32 | $-42.09M |
| Dec 31, 2024 | — | $-47.91M | -0.47 | $-38.26M |
| Dec 31, 2023 | — | $-29.07M | -0.29 | $-31.71M |
| Dec 31, 2022 | — | $-29.15M | -0.45 | $-28.18M |
| Dec 31, 2021 | — | $-33.94M | -1.49 | $-28.95M |
Latest balance sheet: total assets $330.52M, total liabilities $9.01M, cash $54.30M (as of Jun 30, 2026).
TRVI earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $18.50 |
| May 5, 2026 | 8-K Item 2.02 (results) | $14.66 |
| Apr 17, 2026 | 8-K Item 2.02 (results) | $15.23 |
| Mar 17, 2026 | 8-K Item 2.02 (results) | $11.19 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $11.46 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $7.30 |
| May 8, 2025 | 8-K Item 2.02 (results) | $6.60 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $6.56 |
| Jan 8, 2025 | 8-K Item 2.02 (results) | $4.03 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $3.10 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on TRVI
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.